Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative therapies function by mimicking trizepatide the physiological actions of GLP-1, a hormone released by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these agents enhance insulin release a

The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing differences in the